About Mbarara University of Science and Technology
Mbarara University of Science & Technology, commonly known as Mbarara University, is a public university in Uganda. Mbarara University commenced student intake and instruction in 1989. It is one of the ten public universities and degree-awarding institutions in the country.
Clinical Trials at Mbarara University of Science and Technology
During the past decade, Mbarara University of Science and Technology conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 4 clinical trials were completed, i.e. on
average, 15.4% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 3 clinical trials were completed. i.e. 30%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Mbarara University of Science and Technology" #1 sponsor was "Massachusetts General Hospital" with 16 trials, followed by "Mbarara University of Science and Technology" with 8 trials
sponsored, "University of Minnesota" with 2 trials sponsored, "University of North Carolina, Chapel Hill" with 2 trials sponsored and "Bielefeld University"
with 2 trials sponsored. Other sponsors include -3 different institutions and
companies that sponsored additional 7 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Mbarara University of Science and Technology"
#1 collaborator was "Mbarara University of Science and Technology" with 17 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 4 trials as a collaborator, "University of Calgary" with 4 trials as a collaborator, "Alberta Children's Hospital Research Institute" with 3 trials as a collaborator and "The ELMA Foundation" with 3 trials as a collaborator. Other collaborators include 29 different institutions and companies that were
collaborators in the rest 32 trials.
Clinical Trials Conditions at Mbarara University of Science and Technology
According to Clinical.Site data, the most researched conditions in "Mbarara University of Science and Technology" are
"HIV" (4 trials), "Indigency" (3 trials), "AIDS" (2 trials), "Cryptococcal Meningitis" (2 trials) and "HIV Infections" (2 trials). Many other conditions were trialed in "Mbarara University of Science and Technology" in a lesser frequency.
Clinical Trials Intervention Types at Mbarara University of Science and Technology
Most popular intervention types in "Mbarara University of Science and Technology" are "Other" (20 trials), "Behavioral" (4 trials), "Drug" (2 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Survey questionnaire" (6 trials), "Livelihood intervention" (2 trials), "Simulation based learning" (2 trials), "Cepheid Xpert HIV-1 Viral Load Assay" (1 trials) and "Enhanced recovery after surgery (ERAS)" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Mbarara University of Science and Technology
The vast majority of trials in "Mbarara University of Science and Technology" are
25 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.
Clinical Trials Status at Mbarara University of Science and Technology
Currently, there are NaN active trials in "Mbarara University of Science and Technology".
undefined are not yet recruiting,
2 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 18 completed trials in Mbarara University of Science and Technology,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Mbarara University of Science and Technology, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 23 trials that are defined as “Not Applicable".